Cargando…

A Randomized, Multicenter, Prospective, Crossover, Open-Label Study of Factors Associated With Patient Preferences for Naloxegol or PEG 3350 for Opioid-Induced Constipation

OBJECTIVES: To determine patient preference for treating opioid-induced constipation (OIC) using naloxegol or polyethylene glycol (PEG) 3350 in patients receiving opioids for noncancer pain. METHODS: This crossover study included two 2-week active treatment periods, each preceded by a 1-week washout...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brenner, Darren M., Hu, Yiqun, Datto, Catherine, Creanga, Dana, Camilleri, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553549/ https://www.ncbi.nlm.nih.gov/pubmed/31058652 http://dx.doi.org/10.14309/ajg.0000000000000229

Ejemplares similares

Clinical utility of naloxegol in the treatment of opioid-induced constipation
por: Bruner, Heather C, et al.
Publicado: (2015)

Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients’ Health State Utility
por: Lawson, Richard, et al.
Publicado: (2016)

Effectiveness of naloxegol in patients with cancer pain suffering from opioid-induced constipation
por: Lemaire, Antoine, et al.
Publicado: (2021)

Evaluating the Safety and Efficacy of Naloxegol in Critically Ill Opioid-Induced Constipation Patients
por: Rizwan, M. Zeeshan, et al.
Publicado: (2023)

Naloxegol: First oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation
por: Anantharamu, Tejus, et al.
Publicado: (2015)

Naloxegol in opioid-induced constipation: a new paradigm in the treatment of a common problem
por: Yoon, Stephanie C, et al.
Publicado: (2017)

Correction to: Effectiveness of naloxegol in patients with cancer pain suffering from opioid‑induced constipation
por: Lemaire, Antoine, et al.
Publicado: (2021)

Pharmacologic Profile of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist, for the Treatment of Opioid-Induced Constipation
por: Floettmann, Eike, et al.
Publicado: (2017)

Population Exposure‐Response Modeling of Naloxegol in Patients With Noncancer‐Related Pain and Opioid‐Induced Constipation
por: Al‐Huniti, N, et al.
Publicado: (2016)

Polyethylene glycol 3350 plus electrolytes for pediatric chronic constipation: An open‐label clinical study in Japan
por: Gondo, Mayuko, et al.
Publicado: (2020)

Population Exposure‐Response Modeling Supported Selection of Naloxegol Doses in Phase III Studies in Patients With Opioid‐Induced Constipation
por: Al‐Huniti, Nidal, et al.
Publicado: (2017)

Naloxegol to Prevent Constipation in ICU Adults Receiving Opioids: A Randomized Double-Blind Placebo-Controlled Pilot Trial
por: Duprey, Matthew S., et al.
Publicado: (2022)

Effect of Naloxegol on Opioid-Induced Esophageal Motility Disorder
por: Ulteig, Crista, et al.
Publicado: (2022)

Efficacy and Safety of Naloxegol in Patients with Chronic Non-Cancer Pain Who Experience Opioid-Induced Constipation: A Pooled Analysis of Two Global, Randomized Controlled Studies
por: Chey, William D, et al.
Publicado: (2023)

Antifibrotic preventive effect of polyethylene glycol (PEG) 3350 in methotrexateinduced hepatoxicity model
por: Acar, Hüseyin, et al.
Publicado: (2022)

A Prospective, Real-World, Multinational Study of Naloxegol for Patients with Cancer Pain Diagnosed with Opioid-Induced Constipation—The NACASY Study
por: Davies, Andrew, et al.
Publicado: (2022)

Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction
por: Poulsen, Jakob Lykke, et al.
Publicado: (2014)

Safety of polyethylene glycol 3350 solution in chronic constipation: randomized, placebo-controlled trial
por: McGraw, Thomas
Publicado: (2016)

Efficacy of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: a 3-month follow-up analysis
por: Cobo Dols, Manuel, et al.
Publicado: (2021)

Using Polyethylene Glycol 3350 Plus Electrolytes in Constipated Hemodialysis Patients: A Case Series
por: Endo, Hiroyuki, et al.
Publicado: (2020)

Magnetite Nanoparticles Coated with PEG 3350-Tween 80: In Vitro Characterization Using Primary Cell Cultures
por: Roacho-Pérez, Jorge A, et al.
Publicado: (2020)

Clinical efficacy and safety of polyethylene glycol 3350 versus liquid paraffin in the treatment of pediatric functional constipation
por: Rafati, MR., et al.
Publicado: (2011)

Polyethylene Glycol 3350 With Electrolytes Versus Polyethylene Glycol 4000 for Constipation: A Randomized, Controlled Trial
por: Bekkali, Noor L.H., et al.
Publicado: (2018)

Polyethylene Glycol 3350 in the Treatment of Chronic Idiopathic Constipation: Post hoc Analysis Using FDA Endpoints
por: Menees, Stacy B., et al.
Publicado: (2022)

Methylprednisolone/peg-3350/sodium-chloride/sodium-bicarbonate/potassium-chloride/phenoxymethylpenicillin: Anaphylaxis to the polyethylene glycol (PEG) excipients : 2 case reports
Publicado: (2022)

Efficacy and Safety of Combined Oral and Enema Therapy Using Polyethylene Glycol 3350-Electrolyte for Disimpaction in Pediatric Constipation
por: Yoo, Taeyeon, et al.
Publicado: (2017)

Absorption, distribution, metabolism, and excretion of [(14)C]-labeled naloxegol in healthy subjects
por: Bui, Khanh, et al.
Publicado: (2015)

Satisfaction with Therapy Among Patients with Chronic Noncancer Pain with Opioid-Induced Constipation
por: LoCasale, Robert J., et al.
Publicado: (2016)

The Burden of Opioid-Induced Constipation: Discordance Between Patient and Health Care Provider Reports
por: LoCasale, Robert J., et al.
Publicado: (2016)

SPIE Technical Conference 3350 on Astronomical Interferometry
por: Reasenberg, R, et al.
Publicado: (1998)

Polyethylene glycol 3350 plus electrolytes for chronic constipation: a 2-week, randomized, double-blind, placebo-controlled study with a 52-week open-label extension
por: Nakajima, Atsushi, et al.
Publicado: (2019)

Patient Preferences for Change in Symptoms Associated with Opioid-Induced Constipation
por: Epstein, Robert S., et al.
Publicado: (2014)

Naloxegol and Postoperative Urinary Retention: A Randomized Trial
por: Turan, Alparslan, et al.
Publicado: (2022)

Resource use and costs associated with opioid-induced constipation following total hip or total knee replacement surgery
por: Wittbrodt, Eric T, et al.
Publicado: (2018)

Opioid-induced constipation: rationale for the role of norbuprenorphine in buprenorphine-treated individuals
por: Webster, Lynn R, et al.
Publicado: (2016)

Improved Process for the Preparation of Naloxegol Oxalate, an Opiod Receptor Antagonist
por: Velugula, Siva Rama Kasibabu, et al.
Publicado: (2023)

A227 THE EFFECTIVENESS OF PEG 3350 COMPARED TO LACTULOSE FOR THE TREATMENT OF ACUTE HEPATIC ENCEPHALOPATHY IN ADULT CIRRHOTIC PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Afzaal, T, et al.
Publicado: (2022)

Update on the role of naldemedine in opioid-induced constipation in patients with chronic noncancer pain
por: BouSaba, Joelle, et al.
Publicado: (2022)

Naloxegol hydrogen oxalate displaying a hydrogen-bonded layer structure
por: Gelbrich, Thomas, et al.
Publicado: (2018)

Can Naloxegol Therapy Improve Quality of Life in Patients with Advanced Cancer?
por: Ostan, Rita, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2t5111dkl2k2rtasrhkqhbqgqe